RxDoctor Payments DataLook up a doctor →

Nita Chatterjee, MD

Family Medicine · North Grosvenordale, CTNPI 1164469854

Payments from drug & device makers

$21,883in general payments, 2019–2025

Across 849 payments — averaging $25.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$2K
  • GSK$2K
  • Boehringer Ingelheim$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • plus $10K from 50 others

What the payments were for

  • Food & beverage$21,63299%
  • Education$2511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,883 in reported general payments places this provider in the 95th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$92,050
Medicare patients
154
Services billed
1,150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$113,379
JardianceEmpagliflozin61$78,822
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$60,854
EliquisApixaban39$46,977
ProliaDenosumab17$29,784
MyrbetriqMirabegron15$20,699
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$11,717
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,805
SynthroidLevothyroxine Sodium54$5,095
Rosuvastatin Calcium277$4,229
Gabapentin134$3,295
Pantoprazole Sodium168$2,427
Atorvastatin Calcium295$2,402
Valsartan87$2,212
Raloxifene Hcl53$2,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,619$113,37973 claims
Boehringer IngelheimJardiance$1,627$78,82261 claims
GSKTrelegy Ellipta$1,966$60,85441 claims
PfizerEliquis$740$46,97739 claims
AmgenProlia$1,004$29,78417 claims
Astellas Pharma US IncMyrbetriq$174$20,69915 claims
AstraZenecaBreztri Aerosphere$3,184$7,80512 claims
AbbVieSynthroid$2,264$5,09554 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$53$94495 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 family medicine providers in Connecticut.

Other family medicine in North Grosvenordale

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →